Drug manufacturers are urging the Health Resources and Services Administration to rework the 340B ceiling price rule after HRSA pushed back its implementation citing ongoing questions, but 340B providers say the rule should be implemented immediately because it is already more than six years after the statutory deadline and stakeholders have had many chances to weigh in. The rule was finalized shortly before President Obama left office, but its implementation was put on hold by the Trump administration. The rule...